| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD276 | Synonyms | 4Ig-B7-H3, B7-H3, B7H3, B7RP-2 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q24.1 | dbXrefs | |
| Description | CD276 molecule | ||||
| GTO ID | GTC2406 |
| Trial ID | NCT04483778 |
| Disease | Pediatric Solid Tumor | Germ Cell Tumor | Hepatoblastoma | Rhabdoid Tumor | Carcinoma | Melanoma | Neuroblastoma | Ewing Sarcoma | Rhabdomyosarcoma | Clear Cell Sarcoma | Childhood Soft Tissue Sarcoma | Retinoblastoma | Synovial Sarcoma | Peripheral Nerve Sheath Neoplasm | Osteosarcoma | Desmoplastic Small Round Cell Tumor |
| Altered gene | CD276|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SCRI-CARB7H3(s)|SCRI-CARB7H3(s)x19 |
| Co-treatment | pembrolizumab |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | B7-H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
| Year | 2020 |
| Country | United States |
| Company sponsor | Seattle Children's Hospital |
| Other ID(s) | STRIvE-02 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||||||
|
|||||||||||||